{"entity":{"type":"insider","cik":"0001565832","url":"/insider/0001565832","json_url":"/insider/0001565832.json","name":"TRAVERSA SERGIO","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":51,"n_filings":18,"first":"2015-12-16","last":"2025-12-16","span_basis":"filed_date"},"name_variants":[{"name":"TRAVERSA SERGIO","source":"filing","n_filings":18,"first_seen":"2015-12-16","last_seen":"2025-12-16"}],"transactions":[{"id":4491954,"accession":"0001213900-25-121974","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-25-121974","line_url":"/filing/0001213900-25-121974#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27500.0,"shares_display":"27,500","price_per_share":4.12,"price_display":"4.12","price_state":"stated","total_value":113300.0,"total_display":"113,300.00","total_whole":"113,300","shares_owned_after":1300000.0,"shares_owned_after_display":"1,300,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-15","filed_date":"2025-12-16","scope":"insider"},{"id":4992186,"accession":"0001213900-25-106837","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-25-106837","line_url":"/filing/0001213900-25-106837#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":272500.0,"shares_display":"272,500","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":599500.0,"total_display":"599,500.00","total_whole":"599,500","shares_owned_after":1272500.0,"shares_owned_after_display":"1,272,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-11-05","filed_date":"2025-11-06","scope":"insider"},{"id":4203231,"accession":"0001213900-25-081837","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-25-081837","line_url":"/filing/0001213900-25-081837#line-3","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55976.0,"shares_display":"55,976","price_per_share":0.74,"price_display":"0.74","price_state":"stated","total_value":41422.24,"total_display":"41,422.24","total_whole":"41,422","shares_owned_after":1000000.0,"shares_owned_after_display":"1,000,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-28","filed_date":"2025-08-28","scope":"insider"},{"id":4203228,"accession":"0001213900-25-081837","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-25-081837","line_url":"/filing/0001213900-25-081837#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":129455.0,"shares_display":"129,455","price_per_share":0.67,"price_display":"0.67","price_state":"stated","total_value":86734.85,"total_display":"86,734.85","total_whole":"86,735","shares_owned_after":944024.0,"shares_owned_after_display":"944,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-27","filed_date":"2025-08-28","scope":"insider"},{"id":4203224,"accession":"0001213900-25-081837","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-25-081837","line_url":"/filing/0001213900-25-081837#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":80545.0,"shares_display":"80,545","price_per_share":0.62,"price_display":"0.62","price_state":"stated","total_value":49937.9,"total_display":"49,937.90","total_whole":"49,938","shares_owned_after":814569.0,"shares_owned_after_display":"814,569","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-26","filed_date":"2025-08-28","scope":"insider"},{"id":4272418,"accession":"0001213900-25-046085","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-25-046085","line_url":"/filing/0001213900-25-046085#line-3","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":147686.0,"shares_display":"147,686","price_per_share":0.5569,"price_display":"0.56","price_state":"stated","total_value":82246.3334,"total_display":"82,246.33","total_whole":"82,246","shares_owned_after":734024.0,"shares_owned_after_display":"734,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-20","filed_date":"2025-05-20","scope":"insider"},{"id":4272413,"accession":"0001213900-25-046085","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-25-046085","line_url":"/filing/0001213900-25-046085#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":30000.0,"shares_display":"30,000","price_per_share":0.4998,"price_display":"0.50","price_state":"stated","total_value":14994.0,"total_display":"14,994.00","total_whole":"14,994","shares_owned_after":586338.0,"shares_owned_after_display":"586,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-19","filed_date":"2025-05-20","scope":"insider"},{"id":4272408,"accession":"0001213900-25-046085","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-25-046085","line_url":"/filing/0001213900-25-046085#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":172314.0,"shares_display":"172,314","price_per_share":0.4496,"price_display":"0.45","price_state":"stated","total_value":77472.3744,"total_display":"77,472.37","total_whole":"77,472","shares_owned_after":556338.0,"shares_owned_after_display":"556,338","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-05-16","filed_date":"2025-05-20","scope":"insider"},{"id":2852702,"accession":"0001213900-24-077795","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-24-077795","line_url":"/filing/0001213900-24-077795#line-3","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":51407.0,"shares_display":"51,407","price_per_share":2.99,"price_display":"2.99","price_state":"stated","total_value":153706.93,"total_display":"153,706.93","total_whole":"153,707","shares_owned_after":384024.0,"shares_owned_after_display":"384,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-11","scope":"insider"},{"id":2852695,"accession":"0001213900-24-077795","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-24-077795","line_url":"/filing/0001213900-24-077795#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":33014.0,"shares_display":"33,014","price_per_share":2.75,"price_display":"2.75","price_state":"stated","total_value":90788.5,"total_display":"90,788.50","total_whole":"90,789","shares_owned_after":332617.0,"shares_owned_after_display":"332,617","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-10","filed_date":"2024-09-11","scope":"insider"},{"id":2852688,"accession":"0001213900-24-077795","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-24-077795","line_url":"/filing/0001213900-24-077795#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55579.0,"shares_display":"55,579","price_per_share":2.71,"price_display":"2.71","price_state":"stated","total_value":150619.09,"total_display":"150,619.09","total_whole":"150,619","shares_owned_after":299603.0,"shares_owned_after_display":"299,603","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-09","filed_date":"2024-09-11","scope":"insider"},{"id":3171162,"accession":"0001213900-24-008560","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-24-008560","line_url":"/filing/0001213900-24-008560#line-3","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":27460.0,"shares_display":"27,460","price_per_share":3.9968,"price_display":"4.00","price_state":"stated","total_value":109752.128,"total_display":"109,752.13","total_whole":"109,752","shares_owned_after":244024.0,"shares_owned_after_display":"244,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-31","filed_date":"2024-01-31","scope":"insider"},{"id":3171157,"accession":"0001213900-24-008560","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-24-008560","line_url":"/filing/0001213900-24-008560#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":40999.0,"shares_display":"40,999","price_per_share":3.9013,"price_display":"3.90","price_state":"stated","total_value":159949.3987,"total_display":"159,949.40","total_whole":"159,949","shares_owned_after":216564.0,"shares_owned_after_display":"216,564","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-30","filed_date":"2024-01-31","scope":"insider"},{"id":3171153,"accession":"0001213900-24-008560","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-24-008560","line_url":"/filing/0001213900-24-008560#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31541.0,"shares_display":"31,541","price_per_share":3.7106,"price_display":"3.71","price_state":"stated","total_value":117036.0346,"total_display":"117,036.03","total_whole":"117,036","shares_owned_after":175565.0,"shares_owned_after_display":"175,565","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-29","filed_date":"2024-01-31","scope":"insider"},{"id":6436091,"accession":"0001213900-22-079244","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-079244","line_url":"/filing/0001213900-22-079244#line-1","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":55250.0,"shares_display":"55,250","price_per_share":2.096,"price_display":"2.10","price_state":"stated","total_value":115804.0,"total_display":"115,804.00","total_whole":"115,804","shares_owned_after":144024.0,"shares_owned_after_display":"144,024","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-12-08","filed_date":"2022-12-12","scope":"insider"},{"id":6754979,"accession":"0001213900-22-037231","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001213900-22-037231","line_url":"/filing/0001213900-22-037231","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13755.0,"shares_display":"13,755","price_per_share":18.413382769901855,"price_display":"18.41","price_state":"stated","total_value":253276.08,"total_display":"253,276.08","total_whole":"253,276","shares_owned_after":92842.0,"shares_owned_after_display":"92,842","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-01","filed_date":"2022-07-05","scope":"insider","n_lines":3},{"id":6754970,"accession":"0001213900-22-037231","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-22-037231","line_url":"/filing/0001213900-22-037231","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16012.0,"shares_display":"16,012","price_per_share":19.129475393454907,"price_display":"19.13","price_state":"stated","total_value":306301.16,"total_display":"306,301.16","total_whole":"306,301","shares_owned_after":88774.0,"shares_owned_after_display":"88,774","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-30","filed_date":"2022-07-05","scope":"insider","n_lines":2},{"id":5119170,"accession":"0001213900-21-014918","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-21-014918","line_url":"/filing/0001213900-21-014918#line-4","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2983.0,"shares_display":"2,983","price_per_share":35.0908,"price_display":"35.09","price_state":"stated","total_value":104675.8564,"total_display":"104,675.86","total_whole":"104,676","shares_owned_after":88774.0,"shares_owned_after_display":"88,774","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-10","filed_date":"2021-03-11","scope":"insider"},{"id":5119166,"accession":"0001213900-21-014918","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-21-014918","line_url":"/filing/0001213900-21-014918","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7017.0,"shares_display":"7,017","price_per_share":35.651855280034205,"price_display":"35.65","price_state":"stated","total_value":250169.0685,"total_display":"250,169.07","total_whole":"250,169","shares_owned_after":93937.0,"shares_owned_after_display":"93,937","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-09","filed_date":"2021-03-11","scope":"insider","n_lines":2},{"id":4905104,"accession":"0001213900-21-012174","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-21-012174","line_url":"/filing/0001213900-21-012174","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":34.23920574,"price_display":"34.24","price_state":"stated","total_value":342392.0574,"total_display":"342,392.06","total_whole":"342,392","shares_owned_after":89077.0,"shares_owned_after_display":"89,077","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-24","filed_date":"2021-02-26","scope":"insider","n_lines":3},{"id":5349132,"accession":"0001213900-21-009699","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-21-009699","line_url":"/filing/0001213900-21-009699#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1446.0,"shares_display":"1,446","price_per_share":35.4346,"price_display":"35.43","price_state":"stated","total_value":51238.4316,"total_display":"51,238.43","total_whole":"51,238","shares_owned_after":88774.0,"shares_owned_after_display":"88,774","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-11","filed_date":"2021-02-16","scope":"insider"},{"id":5057605,"accession":"0001213900-21-008204","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-21-008204","line_url":"/filing/0001213900-21-008204#line-4","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1930.0,"shares_display":"1,930","price_per_share":35.2835,"price_display":"35.28","price_state":"stated","total_value":68097.155,"total_display":"68,097.16","total_whole":"68,097","shares_owned_after":88774.0,"shares_owned_after_display":"88,774","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-10","filed_date":"2021-02-10","scope":"insider"},{"id":5057601,"accession":"0001213900-21-008204","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-21-008204","line_url":"/filing/0001213900-21-008204#line-3","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5963.0,"shares_display":"5,963","price_per_share":35.2069,"price_display":"35.21","price_state":"stated","total_value":209938.7447,"total_display":"209,938.74","total_whole":"209,939","shares_owned_after":90704.0,"shares_owned_after_display":"90,704","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-10","scope":"insider"},{"id":5057596,"accession":"0001213900-21-008204","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-21-008204","line_url":"/filing/0001213900-21-008204#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3313.0,"shares_display":"3,313","price_per_share":35.0283,"price_display":"35.03","price_state":"stated","total_value":116048.7579,"total_display":"116,048.76","total_whole":"116,049","shares_owned_after":96667.0,"shares_owned_after_display":"96,667","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-08","filed_date":"2021-02-10","scope":"insider"},{"id":4494032,"accession":"0001213900-21-006834","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-21-006834","line_url":"/filing/0001213900-21-006834#line-3","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":35.0,"price_display":"35.00","price_state":"stated","total_value":3500.0,"total_display":"3,500.00","total_whole":"3,500","shares_owned_after":88874.0,"shares_owned_after_display":"88,874","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-03","filed_date":"2021-02-04","scope":"insider"},{"id":4494027,"accession":"0001213900-21-006834","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-21-006834","line_url":"/filing/0001213900-21-006834#line-2","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3178.0,"shares_display":"3,178","price_per_share":35.0754,"price_display":"35.08","price_state":"stated","total_value":111469.6212,"total_display":"111,469.62","total_whole":"111,470","shares_owned_after":88874.0,"shares_owned_after_display":"88,874","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-02-02","filed_date":"2021-02-04","scope":"insider"},{"id":4631776,"accession":"0001213900-21-005448","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-21-005448","line_url":"/filing/0001213900-21-005448","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":32.391441,"price_display":"32.39","price_state":"stated","total_value":323914.41,"total_display":"323,914.41","total_whole":"323,914","shares_owned_after":75593.0,"shares_owned_after_display":"75,593","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-27","filed_date":"2021-01-29","scope":"insider","n_lines":3},{"id":5119103,"accession":"0001213900-21-004480","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001213900-21-004480","line_url":"/filing/0001213900-21-004480#line-5","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":600.0,"shares_display":"600","price_per_share":35.15,"price_display":"35.15","price_state":"stated","total_value":21090.0,"total_display":"21,090.00","total_whole":"21,090","shares_owned_after":75493.0,"shares_owned_after_display":"75,493","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-26","filed_date":"2021-01-26","scope":"insider"},{"id":5119098,"accession":"0001213900-21-004480","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-21-004480","line_url":"/filing/0001213900-21-004480#line-4","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1300.0,"shares_display":"1,300","price_per_share":35.29,"price_display":"35.29","price_state":"stated","total_value":45877.0,"total_display":"45,877.00","total_whole":"45,877","shares_owned_after":76093.0,"shares_owned_after_display":"76,093","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-25","filed_date":"2021-01-26","scope":"insider"},{"id":5119093,"accession":"0001213900-21-004480","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-21-004480","line_url":"/filing/0001213900-21-004480","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2170.0,"shares_display":"2,170","price_per_share":35.582,"price_display":"35.58","price_state":"stated","total_value":77212.94,"total_display":"77,212.94","total_whole":"77,213","shares_owned_after":77827.0,"shares_owned_after_display":"77,827","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-01-22","filed_date":"2021-01-26","scope":"insider","n_lines":2},{"id":2559387,"accession":"0001213900-16-012630","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-16-012630","line_url":"/filing/0001213900-16-012630#line-2","is_derivative":false,"issuer_cik":"0001388320","issuer_name":"Actinium Pharmaceuticals, Inc.","issuer_ticker":"ATNM","issuer_name_source":null,"issuer_url":"/issuer/0001388320","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":2.02,"price_display":"2.02","price_state":"stated","total_value":2020.0,"total_display":"2,020.00","total_whole":"2,020","shares_owned_after":3000.0,"shares_owned_after_display":"3,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-15","filed_date":"2016-04-18","scope":"insider"},{"id":2559384,"accession":"0001213900-16-012630","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-16-012630","line_url":"/filing/0001213900-16-012630#line-1","is_derivative":false,"issuer_cik":"0001388320","issuer_name":"Actinium Pharmaceuticals, Inc.","issuer_ticker":"ATNM","issuer_name_source":null,"issuer_url":"/issuer/0001388320","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":2.02,"price_display":"2.02","price_state":"stated","total_value":4040.0,"total_display":"4,040.00","total_whole":"4,040","shares_owned_after":2000.0,"shares_owned_after_display":"2,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-14","filed_date":"2016-04-18","scope":"insider"},{"id":8097374,"accession":"0001213900-15-009534","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001213900-15-009534","line_url":"/filing/0001213900-15-009534","is_derivative":false,"issuer_cik":"0001553643","issuer_name":"RELMADA THERAPEUTICS, INC.","issuer_ticker":"RLMD","issuer_name_source":null,"issuer_url":"/issuer/0001553643","owner_cik":"0001565832","owner_name":"TRAVERSA SERGIO","owner_display_name":"TRAVERSA SERGIO","owner_url":"/insider/0001565832","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":18970.0,"shares_display":"18,970","price_per_share":3.0465002635740643,"price_display":"3.05","price_state":"stated","total_value":57792.11,"total_display":"57,792.11","total_whole":"57,792","shares_owned_after":331322.0,"shares_owned_after_display":"331,322","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-12-15","filed_date":"2015-12-17","scope":"insider","n_lines":9}],"collapsed":true,"next_cursor":"2015-12-15|8097360","ledger_fault":false,"count":{"value":51,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":27,"open_market":true},{"code":"S","label":"Open-market sale","n":24,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":51},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001553643","name":"RELMADA THERAPEUTICS, INC.","url":"/issuer/0001553643","role":"Director, Officer (Chief Executive Officer)","n_filings":17,"first_seen":"2015-12-16","last_seen":"2025-12-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001388320","name":"Actinium Pharmaceuticals, Inc.","url":"/issuer/0001388320","role":"Director","n_filings":1,"first_seen":"2016-04-18","last_seen":"2016-04-18"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001565832","retrieved_at":"2026-08-24T03:00:06+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}